Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Clinical Cancer Research

• Publication date

  2012-02-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-11-2614PMID 22371455PMCID PMC3759995
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Annals of Thoracic Surgery.

  2014cited by this paper
• Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways.

  2012cited by this paper
• Animal models and molecular imaging tools to investigate lymph node metastases

  2011cited by this paper
• A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation

  2011cited by this paper
• MT1-MMP plays an important role in an invasive activity of malignant pleural mesothelioma cell.

  2011cited by this paper
• Pre‐Clinical Mouse Models of Primary and Metastatic Pleural Cancers of the Lung and Breast and the Use of Bioluminescent Imaging to Monitor Pleural Tumor Burden

  2011cited by this paper
• An In Vivo Platform for Tumor Biomarker Assessment

  2011cited by this paper
• Pleomorphic Epithelioid Diffuse Malignant Pleural Mesothelioma: A Clinicopathological Review and Conceptual Proposal to Reclassify as Biphasic or Sarcomatoid Mesothelioma

  2011cited by this paper
• Ranpirnase Interferes with NF-κB Pathway and MMP9 Activity, Inhibiting Malignant Mesothelioma Cell Invasiveness and Xenograft Growth.

  2011cited by this paper
• Modulators of cancer cell invasiveness

  2010cited by this paper
• Serum Soluble Mesothelin Concentrations in Malignant Pleural Mesothelioma: Relationship to Tumor Volume, Clinical Stage and Changes in Tumor Burden

  2010cited by this paper
• Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.

  2010cited by this paper
• Re-evaluation of histological diagnoses of malignant mesothelioma by immunohistochemistry

  2010cited by this paper
• Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels

  2010cited by this paper
• Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases

  2010cited by this paper
• Frequency of Use and Predictors of Cancer-Directed Surgery in the Management of Malignant Pleural Mesothelioma in a Community-Based (Surveillance, Epidemiology, and End Results [SEER]) Population

  2010cited by this paper
• Serum level of expressed in renal carcinoma (ERC)/ mesothelin in rats with mesothelial proliferative lesions induced by multi-wall carbon nanotube (MWCNT).

  2010cited by this paper
• Modulation of MMP-2 and MMP-9 by cytokines, mitogens and inhibitors in lung cancer and malignant mesothelioma cell lines.

  2009cited by this paper
• Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains

  2009cited by this paper
• Role of Immunohistochemical Overexpression of Matrix Metalloproteinases MMP-2 and MMP-11 in the Prognosis of Death by Ovarian Cancer

  2009cited by this paper
• Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway.

  2009cited by this paper
• Circulating Mesothelin Protein and Cellular Antimesothelin Immunity in Patients with Pancreatic Cancer

  2009cited by this paper
• An animal model of preclinical diagnosis of pancreatic ductal adenocarcinomas.

  2009cited by this paper
• Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer.

  2008cited by this paper
• Prognostic significance of MMP‐9 and TIMP‐1 serum and tissue expression in breast cancer

  2008cited by this paper
• Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.

  2008cited by this paper
• Identification of Proteins Associating with Glycosylphosphatidylinositol- Anchored T-Cadherin on the Surface of Vascular Endothelial Cells: Role for Grp78/BiP in T-Cadherin-Dependent Cell Survival

  2008cited by this paper
• Mesothelin targeted cancer immunotherapy.

  2008cited by this paper
• Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.

  2008cited by this paper
• Quantitative Monitoring of Adenocarcinoma Development in Rodents by Magnetic Resonance Imaging

  2008cited by this paper
• Mesothelin Promotes Anchorage-Independent Growth and Prevents Anoikis via Extracellular Signal-Regulated Kinase Signaling Pathway in Human Breast Cancer Cells

  2008cited by this paper
• Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center

  2007cited by this paper
• Integrin-linked kinase is an essential mediator for T-cadherin-dependent signaling via Akt and GSK3beta in endothelial cells.

  2007cited by this paper
• Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer

  2007cited by this paper
• Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment

  2007cited by this paper
• Mesothelin Expression in Human Lung Cancer

  2007cited by this paper
• Integrin‐linked kinase is an essential mediator for T‐cadherin‐dependent signaling via Akt and GSK3β in endothelial cells

  2007cited by this paper
• Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.

  2007cited by this paper
• Imaging and therapy of malignant pleural mesothelioma using replication‐competent herpes simplex viruses

  2006cited by this paper
• Minimally invasive localization of oncolytic herpes simplex viral therapy of metastatic pleural cancer

  2006cited by this paper
• Intraoperative localization of lymph node metastases with a replication-competent herpes simplex virus.

  2006cited by this paper
• Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors

  2006cited by this paper
• Positron emission tomography predicts survival in malignant pleural mesothelioma.

  2006cited by this paper
• Matrix metalloproteinases promote inflammation and fibrosis in asbestos-induced lung injury in mice.

  2006cited by this paper
• Extended surgical staging for potentially resectable malignant pleural mesothelioma.

  2005cited by this paper
• From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

  2005influential reference
• Forced expression of deltaN-TCF-1B in colon cancer derived cell lines is accompanied by the induction of CEACAM5/6 and mesothelin.

  2005cited by this paper
• Mesothelin

  2004cited by this paper
• Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera

  2004cited by this paper
• Mesothelin : A New Target for Immunotherapy

  2004cited by this paper
• Comprehensive Analysis of Matrix Metalloproteinase and Tissue Inhibitor Expression in Pancreatic Cancer

  2004cited by this paper
• Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura

  2003cited by this paper
• Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS)

  2003cited by this paper
• Stromelysin-1 and mesothelin are differentially regulated by Wnt-5a and Wnt-1 in C57mg mouse mammary epithelial cells

  2003cited by this paper
• BMC Developmental Biology BioMed Central Research article

  2003cited by this paper
• Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF‐C autocrine loops

  2003cited by this paper
• Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro.

  2002cited by this paper
• Differential Expression and Activity Status of MMP-1, MMP-2 and MMP-9 in Tumor and Stromal Cells of Squamous Cell Carcinomas of the Lung

  2002cited by this paper
• The microenvironment of the tumour–host interface

  2001cited by this paper
• Anti‐β4 integrin antibodies enhance migratory and invasive abilities of human colon adenocarcinoma cells and their MMP‐2 expression

  2000cited by this paper
• Angiogenic cytokines in mesothelioma: a study of VEGF, FGF‐1 and ‐2, and TGF β expression

  1999cited by this paper
• Pleural mesothelioma mimics the integrin profile of activated, sessile rather than detached mesothelial cells

  1997cited by this paper
• The importance of surgical staging in the treatment of malignant pleural mesothelioma.

  1996cited by this paper

• A monoclonal antibody W1 blocks mesothelin-mediated tumor progression

  2025cites this paper
• Circulating Biomarkers and Targeted Therapy in Pleural Mesothelioma

  2025cites this paper
• Anti-MSLN chimeric antigen receptor-like NK cell therapy with tumor-penetrating capacity (uCAR-like NK) for solid tumors

  2025cites this paper
• Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma.

  2025cites this paper
• Molecular Mechanisms of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in Mesothelioma

  2025cites this paper
• ERC/Mesothelin Is Associated with the Formation of Microvilli on the Mesothelium and Has Limited Functional Relevance Under Physiological Conditions

  2025cites this paper
• Targeting mesothelin-CD24 axis repolarizes tumor-associated macrophages to potentiate PD-1 blockade therapy in high-grade serous ovarian cancer

  2025cites this paper
• CAR-T for Lung Cancers: Challenges and Innovations.

  2025cites this paper
• A tumor-on-a-chip for in vitro study of CAR-T cell immunotherapy in solid tumors.

  2025cites this paper
• Regional delivery of mesothelin-targeted chimeric antigen receptor T-cell effectively and safely targets colorectal cancer liver metastases in mice

  2024cites this paper
• Affinity-tuned mesothelin CAR T cells demonstrate enhanced targeting specificity and reduced off-tumor toxicity

  2024cites this paper
• Characterization of mesothelin gene expression in dogs and overexpression in canine mesotheliomas

  2024cites this paper
• Diagnosis of Pleural Mesothelioma: Is Everything Solved at the Present Time?

  2024cites this paper
• Mesothelin expression correlates with elevated inhibitory immune activity in patients with colorectal cancer

  2024cites this paper
• Application of CAR-T cell therapy targeting mesothelin in solid tumor treatment

  2024cites this paper
• Targeted Therapy in Mesotheliomas: Uphill All the Way

  2024cites this paper
• Anoikis-related gene signatures in colorectal cancer: implications for cell differentiation, immune infiltration, and prognostic prediction

  2024cites this paper
• Mesothelin promotes brain metastasis of non-small cell lung cancer by activating MET

  2024cites this paper
• Emerging New Targets in Systemic Therapy for Malignant Pleural Mesothelioma

  2024cites this paper
• Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology.

  2024cites this paper
• Enhanced Expression of Glycolytic Enzymes and Succinate Dehydrogenase Complex Flavoprotein Subunit A by Mesothelin Promotes Glycolysis and Mitochondrial Respiration in Myeloblasts of Acute Myeloid Leukemia

  2024cites this paper
• Mesothelin-targeted MRI for assessing migration, invasion, and prognosis in malignant pleural mesothelioma

  2024cites this paper
• Mesothelin expression correlates with elevated inhibitory immune activity in patients with colorectal cancer

  2023cites this paper
• Organ-specific heterogeneity in tumor-infiltrating immune cells and cancer antigen expression in primary and autologous metastatic lung adenocarcinoma

  2023cites this paper
• The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomas.

  2023cites this paper
• Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?

  2023cites this paper
• A Prospective Clinical Trial to Evaluate Mesothelin as a Biomarker for the Clinical Management of Patients With Esophageal Adenocarcinoma

  2023cites this paper
• High mesothelin expression by immunohistochemistry predicts improved survival in pleural mesothelioma

  2023cites this paper
• High expression of mesothelin in plasma and tissue is associated with poor prognosis and promotes invasion and metastasis in gastric cancer

  2023cites this paper
• High Homogeneity of Mesothelin Expression in Primary and Metastatic Ovarian Cancer

  2023cites this paper
• Diagnostic value of pleural fluid SMRP, CA125, MMP-7, and MMP-9 in malignant pleural effusion

  2023cites this paper
• Targeted thorium-227 conjugates as treatment options in oncology

  2023cites this paper
• The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy

  2023cites this paper
• CAR-T cell immunotherapy for ovarian cancer: hushing the silent killer

  2023cites this paper
• Evolution of Biomarkers and Treatment Outcomes of Immunotherapy in Lung Cancer

  2023cites this paper
• Tumor-targeted non-ablative radiation promotes solid tumor CAR T-cell therapy efficacy.

  2023cites this paper
• Polymorphisms of an oncogenic gene, mesothelin, predict the risk and prognosis of gastric cancer in a Chinese Han population

  2022cites this paper
• Targeting the undruggable oncogenic KRAS: the dawn of hope

  2022cites this paper
• CAR T-cells for colorectal cancer immunotherapy: Ready to go?

  2022cites this paper
• Geldanamycin treatment does not result in anti-cancer activity in a preclinical model of orthotopic mesothelioma

  2022cites this paper
• Single-cell RNA-Seq reveals the potential risk of anti-mesothelin CAR T Cell therapy toxicity to different organs in humans

  2022cites this paper
• Immunotherapy targeting mesothelin in acute myeloid leukemia

  2022cites this paper
• Molecular Determinants of Peritoneal Dissemination in Gastric Adenocarcinoma

  2022cites this paper
• Human Malignant Rhabdoid Tumor Antigens as Biomarkers and Potential Therapeutic Targets

  2022cites this paper
• High mesothelin expression is correlated with non-squamous cell histology and poor survival in cervical cancer: a retrospective study

  2022cites this paper
• From antibodies to living drugs: Quo vadis cancer immunotherapy?

  2021cites this paper
• Picropodophyllin inhibits the growth of pemetrexed-resistant malignant pleural mesothelioma via microtubule inhibition and IGF-1R-, caspase-independent pathways

  2021cites this paper
• Arming T cells to infiltrate pancreatic tumours

  2021cites this paper
• Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.

  2021cites this paper
• Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody–drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors

  2021influential citation
• Matrix Metalloproteinases as Biomarkers and Treatment Targets in Mesothelioma: A Systematic Review

  2021cites this paper
• Hitting the Bull’s-Eye: Mesothelin’s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma

  2021cites this paper
• Chimeric antigen receptor T-cells (CARs) in cancer treatment.

  2021cites this paper
• Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody–drug conjugates from synthetic antibody libraries

  2021cites this paper
• Imaging CAR T-cell kinetics in solid tumors: Translational implications

  2021influential citation
• A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab.

  2021cites this paper
• Metformin Antagonizes Ovarian Cancer Cells Malignancy Through MSLN Mediated IL-6/STAT3 Signaling

  2021cites this paper
• Nanotechnology-based siRNA delivery strategies for treatment of triple negative breast cancer.

  2021cites this paper
• Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer Aggressiveness

  2021cites this paper
• Immunotherapeutic Approaches in Malignant Pleural Mesothelioma

  2021cites this paper
• CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials.

  2021cites this paper
• Emerging biological therapies for the treatment of malignant pleural mesothelioma

  2021cites this paper
• Inhibition of the Histone Methyltransferase EZH2 Enhances Protumor Monocyte Recruitment in Human Mesothelioma Spheroids

  2021cites this paper
• Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors

  2021cites this paper
• A Novel 89Zr-labeled DDS Device Utilizing Human IgG Variant (scFv): “Lactosome” Nanoparticle-Based Theranostics for PET Imaging and Targeted Therapy

  2021cites this paper
• Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin‐targeted therapies

  2021cites this paper
• Anti-Mesothelin CAR T cell therapy for malignant mesothelioma

  2021cites this paper
• Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors

  2020cites this paper
• Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds

  2020cites this paper
• Regulation of invasion and peritoneal dissemination of ovarian cancer by mesothelin manipulation

  2020cites this paper
• PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.

  2020cites this paper
• Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma

  2020cites this paper
• The Evolving Management of Peritoneal Surface Malignancies.

  2020cites this paper
• Mesothelioma Biomarkers: Discovery in Search of Validation.

  2020cites this paper
• Immunotherapy for mesothelioma: rationale and new approaches.

  2020cites this paper
• Genomics and Functional Genomics of Malignant Pleural Mesothelioma

  2020cites this paper
• gC1qR/HABP1/p32 Is a Potential New Therapeutic Target Against Mesothelioma

  2020cites this paper
• In vitro and in vivo laboratory models of pleural disease

  2020cites this paper
• Mesothelioma Biomarkers: A Review Highlighting Contributions from the Early Detection Research Network

  2020cites this paper
• Mesothelial cells regulate immune responses in health and disease: role for immunotherapy in malignant mesothelioma.

  2020cites this paper
• Killing cervical cancer cells by specific chimeric antigen receptor-modified T cells.

  2020cites this paper
• Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)

  2020cites this paper
• The dark side of immunotherapy: pancreatic cancer

  2020influential citation
• Possible reversibility between epithelioid and sarcomatoid types of mesothelioma is independent of ERC/mesothelin expression

  2020cites this paper
• Current Advances in CAR T Cell Therapy for Malignant Mesothelioma

  2020cites this paper
• Antibody–Drug Conjugates for Cancer Therapy

  2020cites this paper
• Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer

  2020cites this paper
• Mesothelin as a biomarker for targeted therapy

  2019cites this paper
• Malignant Mesothelioma and Pseudomyxoma

  2019influential citation
• Immunotherapy of Malignant Peritoneal Mesothelioma and Pseudomyxoma Peritonei

  2019cites this paper
• The Treatment of Malignant Pleural Mesothelioma: From the Current Standard to Novel Possible Therapeutic Strategies

  2019cites this paper
• Generation of a Transgenic BALB/c Mouse Line With Selective Expression of Human Mesothelin in Thyroid Gland: Application in Mesothelin-targeted Immunotherapy

  2019cites this paper
• Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer.

  2019cites this paper
• Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma

  2019cites this paper
• RASSF1A controls tissue stiffness and cancer stem‐like cells in lung adenocarcinoma

  2019cites this paper
• Mesothelin-targeted CAR-T cells for adoptive cell therapy of solid tumors

  2019cites this paper
• Mesothelin expression and its prognostic role according to microsatellite instability status in colorectal adenocarcinoma

  2019cites this paper
• A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer

  2019cites this paper
• Mesothelin-Targeted Agents in Mesothelioma

  2019cites this paper
• Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer.

  2019cites this paper